NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
P/B ratio for NewAmsterdam Pharma Company N.V. (NAMS)
P/B ratio as of 2023: 3.18
According to NewAmsterdam Pharma Company N.V.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.18. At the end of 2022 the company had a P/B ratio of 0.43.
P/B ratio history for NewAmsterdam Pharma Company N.V. from 2020 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.18 |
| 2022 | 0.43 |
| 2021 | 3.48 |
| 2020 | -52.66 |